Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor-negative breast cancer patients with bone metastases
BMC Cancer, 05/22/09

Park H et al. - In a study to evaluate, according to hormone receptor status, the antitumor effects of bisphosphonate (BP) in breast cancer pts with metastatic bone disease, it was confirmed that bisphosphonate treatment can result in a survival benefit in metastatic breast cancer pts with hormone receptor (HR)-negative tumors.

Methods

Of 317 pts with initial bone metastasis and known breast cancer subtypes, 230 pts (72.6%) had HR-positive tumors, and 87 pts (27.4%) had HR-negative tumors.
The primary outcome of overall survival (OS) was assessed, after adjusting for other factors, comparing a group that received BPs with a group that did not.

Results

87.8% of HR-positive and 69.0% of HR-negative pts received BPs with a median number of 17.7 cycles.
Although BP treatment made no survival benefit in HR-positive group, HR-negative pts showed a significant prolonged survival when they received BPs treatment.
In multivariate analysis, disease-free interval >2 yrs, a sum of metastatic sites <3, and BP treatments were significant factors for survival in HR-negative pts.

Next >>
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy,...